| Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. | |
| | |
MedLine Citation:
|
PMID: 20075642 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Paroxetine discontinuation symptoms can at times be severe enough to reduce the quality of life. However, it is currently not possible to predict the occurrence of discontinuation syndrome before the initiation or discontinuation of paroxetine treatment. In this study, we investigated the effects of genetic polymorphisms in the serotonin 1A, 2A, 2C, 3A, and 3B receptor, the serotonin transporter, and the cytochrome P450 2D6 (CYP2D6) genes on the occurrence of paroxetine discontinuation syndrome. A consecutive series of 56 Japanese patients who had a diagnosis of major depressive or anxiety disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were treated with paroxetine. Paroxetine discontinuation syndrome was found in 35.7% of the patients by direct interview. Patients who stopped taking paroxetine abruptly experienced paroxetine discontinuation syndrome significantly more often than patients who had a tapering off of the dosage of medication. Patients who had the -1019C allele experienced paroxetine discontinuation syndrome more frequently than patients who had the -1019G homozygote (nominal P = 0.0423) of the serotonin 1A receptor gene. However, this result did not remain significant after the Bonferroni correction for multiple comparisons. The findings suggest that the abrupt stoppage of medication is a major risk factor for the occurrence of paroxetine discontinuation syndrome and that C(-1019)G polymorphism of the serotonin 1A receptor gene may be related to the occurrence of the syndrome. |
| | |
Authors:
|
Yusuke Murata; Daisuke Kobayashi; Nanae Imuta; Koichi Haraguchi; Ichiro Ieiri; Ryoji Nishimura; Susumu Koyama; Kazunori Mine |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of clinical psychopharmacology Volume: 30 ISSN: 1533-712X ISO Abbreviation: J Clin Psychopharmacol Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-01-15 Completed Date: 2010-03-19 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8109496 Medline TA: J Clin Psychopharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 11-7 Citation Subset: IM |
Affiliation:
|
Department of Psychosomatic Medicine, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antidepressive Agents, Second-Generation / adverse effects*, therapeutic use Anxiety Disorders / drug therapy, genetics Cytochrome P-450 CYP2D6 / genetics Depressive Disorder / drug therapy, genetics Drug Administration Schedule Female Genetic Predisposition to Disease Humans Male Middle Aged Paroxetine / adverse effects*, therapeutic use Polymorphism, Genetic* Receptor, Serotonin, 5-HT1A / genetics Receptor, Serotonin, 5-HT2A / genetics Receptor, Serotonin, 5-HT2C / genetics Receptors, Serotonin / genetics* Receptors, Serotonin, 5-HT3 / genetics Risk Factors Serotonin Plasma Membrane Transport Proteins / genetics* Substance Withdrawal Syndrome / genetics* |
| Chemical | |
Reg. No./Substance:
|
0/Antidepressive Agents, Second-Generation; 0/Receptor, Serotonin, 5-HT2A; 0/Receptor, Serotonin, 5-HT2C; 0/Receptors, Serotonin; 0/Receptors, Serotonin, 5-HT3; 0/Serotonin Plasma Membrane Transport Proteins; 112692-38-3/Receptor, Serotonin, 5-HT1A; 61869-08-7/Paroxetine; EC 1.14.14.1/Cytochrome P-450 CYP2D6 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship ...
Next Document: Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized t...